Abstract | Primary immunodeficiencies are inherited disorders of the immune system, often caused by the mutation of genes required for lymphocyte development and activation. Recently, several studies have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD (which encodes p110δ) and PIK3R1 (which encodes p85α) that cause a combined immunodeficiency syndrome, referred to as activated PI3Kδ syndrome (APDS; also known as p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI)). Paradoxically, both loss-of-function and gain-of-function mutations that affect these genes lead to immunosuppression, albeit via different mechanisms. Here, we review the roles of PI3Kδ in adaptive immunity, describe the clinical manifestations and mechanisms of disease in APDS and highlight new insights into PI3Kδ gleaned from these patients, as well as implications of these findings for clinical therapy.
(APDS; also known as PASLI) is among a growing number of newly defined primary immunodeficiency (PID) syndromes in which the causal mutations have been identified by next-generation sequencing. The clinical manifestations of APDS are diverse and hetero geneous
, but the majority of patients present with recurrent respiratory infections, often associated with airway scarring (bronchiectasis) and ear and sinus damage, which is suggestive of antibody (and thus B cell) deficiency. Severe, recurrent or persistent infections with herpes family viruses, indicating defective T cell function, are also common in this condition and may cause early death in some affected individuals. Many patients develop benign lymphadenopathy, often associ ated with hepatosplenomegaly, and there is a substantially increased risk of B cell lymphoma associated with APDS
. Increased susceptibility to viral infection and poor recall responses of memory T cells differentiate APDS from isolated hypogammaglobulinaemia [1] [2] [3] [4] , hence APDS should be considered a combined immunodeficiency 5 . More than 100 patients have been reported to date with APDS, but the precise incidence is not yet known 6, 7 . APDS is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1 that induce hyperactivation of the protein products p110δ or p85α, respectively [1] [2] [3] [4] . The p85α regulatory subunit and p110δ catalytic subunit together form the heterodimeric lipid kinase PI3Kδ, which is engaged by multiple receptors in cells of the immune system, including the B cell receptor (BCR) and the T cell receptor (TCR), as well as cytokine and co-stimulatory receptors. Homozygous loss-of-function (LOF) mutations in these same subunits cause a distinct and much rarer form of immunodeficiency in humans, which can be recapitulated in mice [8] [9] [10] , and this apparent dichotomy, together with the clinical features of the affected patient groups, has informed our understanding of the role of PI3Kδ in immune cell development and function.
In this Review, we summarize what is known about PI3Kδ, focusing on its regulation of adaptive immune responses. Much of this knowledge derives from studies using gene-targeted mice. We then summarize our current understanding of PI3Kδ deficiency in humans, before describing in greater detail the clinical and immunological manifestations of APDS.
Overview of class I PI3Ks
The class IA PI3Ks are heterodimeric proteins composed of (and named after) a p110α, p110β or p110δ catalytic subunit that constitutively associates with a p85 regulatory subunit; the sole class IB PI3K is composed of the p110γ catalytic subunit that interacts with a p101 or p84 regulatory subunit (TABLE 1) . p110α and p110β are broadly expressed, whereas p110γ and p110δ are predominantly expressed by leukocytes. Although there is substantial potential for redundancy among the catalytic subunits, unique roles for each individual p110 isoform have been described, reflecting their different expression patterns as well as how they are engaged by their respective receptors 8, 11 . For example, p110α is activated by insulin-like receptors and regulates growth, metabo lism and angiogenesis 11 , whereas p110β Activated phosphoinositide 3-kinase-δ (PI3Kδ) syndrome (APDS).The term APDS encompasses two syndromes: APDS1 (also known as PASLI-CD), which results from a mutation in the PIK3CD gene that leads to the hyperactivation of the p110δ subunit of PI3Kδ; and APDS2 (also known as PASLI-R1), which results from a splice mutation in PIK3R1 that leads to exon skipping and produces a truncated p85α protein with reduced inhibition of p110δ.
Primary immunodeficiency (PID) . An inherited disorder of the immune system that leads to recurrent infections and/or immune dysregulation. Currently there are around 84,000 patients diagnosed worldwide with PID.
contributes to metabolic signalling and has been shown to regulate responses of mouse neutrophils to immune complexes 12, 13 . p110γ is highly expressed in myeloid cells and contributes to chemotactic responses, as well as the production of reactive oxygen species (ROS) by neutrophils 14 . Together with p110δ, p110γ is also important during pre-T cell development in the thymus 15 . p110δ, which is the focus of this Review, is highly expressed both in lymphocytes and myeloid cells and is activated by antigen receptors, co-stimulatory receptors, cytokine receptors and growth factor receptors 8 . Class I PI3Ks catalyse the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) to generate phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), which acts as a membrane tether for cell signalling proteins with pleckstrin homology (PH) domains. Prominent among these are phosphoinositidedependent kinase 1 (PDK1) and AKT, which act in concert to phosphorylate substrates such as the FOXO transcription factors (which become inactivated) and regulators of the mechanistic target of rapamycin (mTOR) complex 1 (which becomes activated). Class IA PI3K regulatory subunits are encoded by three different genes (PIK3R1, PIK3R2 and PIK3R3) (TABLE 1) . PIK3R1 encodes p85α, p55α and p50α (each from a different transcription start site), PIK3R2 encodes p85β, and PIK3R3 encodes p55γ 16 . These regu latory subunits have SH2 domains, which bind phosphorylated YXXM motifs of cell surface receptors and membrane-associated proteins. p85α, p55α, p50α and p85β are ubiqui tously expressed, whereas p55γ is mainly expressed in the brain and testes 16 . Any of the class IA PI3K regulatory subunits can bind to p110α, p110β and p110δ without apparent selectivity. PI3Kδ is best understood to comprise p85α with p110δ, but association between p110δ and any of the other class IA PI3K regulatory subunits is also possible. It is also important to recognize that p85α has many p110δ-independent functions, as it can also bind p110α and p110β 16 . The class IA PI3K regulatory subunits influence the p110 catalytic subunits in three ways 17 : they prevent proteolytic degradation of p110; they inhibit p110 catalytic activity; and they recruit the p110 subunit to tyrosine phosphorylated proteins at the plasma membrane.
Once the SH2 domains of p85α are engaged by phosphotyrosines, the inhibitory contacts with p110 are relieved 17 . Thus, mutations in the PIK3R1 gene can influence PI3K activity by allowing the degradation of p110δ or by diminishing its recruitment to receptors (in the case of PIK3R1 null or LOF mutations), or by releasing the inhibitory action of p85α on p110δ (in the case of PIK3R1 GOF mutations). In addition to the regu latory subunits, p110α and p110δ can bind RAS and p110β binds RAC and CDC42. These small GTPases help tether the p110 subunit to the membrane once it has been recruited to a receptor via its regulatory subunit 17, 18 .
PI3Kδ and immunity: lessons from mice
Before the description of APDS, most of our knowledge of the role of PI3Kδ in immunity and infection was based on genetic and pharmacological studies using mouse models. The GOF mutations that cause APDS have recently been shown to result in increased basal and stimulated PtdIns(3,4,5)P 3 levels and PtdIns(3,4,5)P 3 -dependent signalling cascades in patient-derived lymphocytes [1] [2] [3] [4] , and the study of these patients may give us new insights into how the balance of PI3Kδ activity regulates immune cell functions. Here, we summarize what these studies in mice have taught us, before describing the immunological phenotypes of human patients with mutations in PIK3R1 or PIK3CD.
Loss of PI3Kδ function in mouse B cells. In mice, early B cell development in the bone marrow is only mildly affected by the loss of p85α or p110δ [19] [20] [21] [22] [23] , whereas the
Box 1 | Clinical features of APDS
Patients with activated phosphoinositide 3-kinase-δ (PI3Kδ) syndrome (APDS) display features of both immune deficiency and of immune dysregulation:
• Recurrent lung, ear and sinus infections (with encapsulated bacteria such as Haemophilus influenzae and Streptococcus pneumoniae, which require opsonization for effective killing) are near-universal and are associated with a high incidence of organ damage, including hearing impairment and bronchiectasis (permanent airway scaring) [1] [2] [3] [4] .
• Severe, recurrent or persistent infections with herpes family viruses are common, in particular chronic Epstein-Barr virus (EBV) or cytomegalovirus (CMV) viraemia, and herpes simplex virus (HSV) and varicella zoster virus (VZV) infections 1, [3] [4] [5] [6] [7] . Frequent isolates of some respiratory viruses such as adenovirus and echovirus have also been described 1 .
• Opportunistic infections are rare, although a few patients have experienced recurrent viral warts or molluscum contagiosum infections 49 .
• An increased incidence of abscess formation, lymphadenitis and cellulitis with Gram-positive bacteria (mainly Staphylococcus aureus), and defective killing of mycobacteria by macrophages isolated from a patient with APDS suggest a mild deficit in innate immunity 1, 64 .
• Benign lymphoproliferation (lymphadenopathy, hepatosplenomegaly and focal nodular lymphoid hyperplasia) is a common feature of all APDS cohorts that have been studied to date.
• Histopathological analysis of lymphoid tissue from affected patients demonstrates atypical follicular hyperplasia with attenuation of mantle zones in APDS1, and small B cell follicles in APDS2. Germinal centres were disrupted by infiltrating T cells (often PD1 + ) in both APDS1 and APDS2 6, 7 .
• There is a high frequency of lymphoma associated with APDS, encompassing a wide range of histopathological patterns 1, 2, 7, 65, 67 .
• Immune cytopaenias (thrombocytopaenia, haemolytic anaemia and neutropaenia) and autoimmune-like solid organ conditions (such as juvenile arthritis, glomerulonephritis, thyroiditis and sclerosing cholangitis) have also been reported 7, 66 , with a frequency of 34% in a cohort of 53 patients with APDS1 (REF. 7 ) and 17% in a cohort of 36 patients with APDS2 (REF. 6 ). Mild developmental delays have been observed in both APDS1 and APDS2 cohorts, with a higher incidence in APDS2 (31% versus 19%) 6, 7 .
• Growth retardation is common in patients with APDS2 (REFS 6, 73, 74) but does not seem to be a feature of APDS1 and may relate to the association of heterozygous mutations in PIK3R1 with SHORT (short stature, hyperextensibility of joints, hernia, ocular depression, Rieger anomaly and teething delay) syndrome [88] [89] [90] [91] .
Hypogammaglobulinaemia
An immune disorder characterized by low serum IgG levels.
Immune complexes
Complexes of antigen bound to antibody and, sometimes, components of the complement system. The levels of immune complexes are increased in many autoimmune disorders, in which they become deposited in tissues and cause tissue damage.
Class-switch recombination [19] [20] [21] [22] [23] . PI3Kδ couples BCR activation with both PtdIns(3,4,5)P 3 production and signalling events downstream of the BCR (FIG. 1) . PI3Kδ-deficient B cells fail to respond to mitogenic stimuli, but undergo class-switch recombination (CSR) in response to interleukin-4 (IL-4) and lipopoly saccharide in vitro [19] [20] [21] [22] [23] [24] [25] [26] . However, mice lacking p110δ selectively in B cells can produce high-affinity IgG antibodies in response to immunization with the T cell-dependent (TD) antigen NP-CGG 27 (but as discussed later, germline loss of PIK3R1 or PIK3CD leads to attenuated TD antibody responses). By contrast, PI3Kδ activity within B cells is required for T cell-independent (TI) antibody responses. This may be due in part to the loss of B1 and MZ B cell subsets, which are the dominant B cell subsets that respond to TI antigens, in PI3Kδ-deficient mice 21, 22, 27, 28 .
Consequences of hyperactive PI3Kδ signalling in B cells in mice.
While there are several mouse models of LOF mutations in Pik3cd, the phenotype of Pik3cd GOFmutant mice remains to be described. We can, however, make inferences from other models of hyperactive PI3K signalling (in which Pten or forkhead box O1 (Foxo1) is ablated in the germline or in B cells) or from mice expressing a membrane-bound form of p110α in B cells.
PTEN antagonizes PI3K signalling and hence its ablation leads to elevated PtdIns(3,4,5)P 3 levels. FOXO transcription factors are negatively regulated by PI3K-AKT, and hence their loss mimics some of the effects of hyperactive PI3K-AKT signalling. FOXO transcription factors induce the expression of genes involved in immunoglobulin gene recombination and development such as recombinase-activating gene 1 (Rag1), Rag2, Ikaros and Il7a [29] [30] [31] (FIG. 1) . Failure to undergo VDJ recombination because of elevated PI3K signalling and subsequent inactivation of FOXO1 can lead to a partial block of B cell development in the bone marrow 29, 30 . In addition, elevated PI3K signalling can increase the sensitivity of developing Pten-null B cells to negative selection by self antigens 32 . Interference with RAG expression and/or negative selection may lead to the development of B cells with aberrant phenotypes, as observed in patients with APDS (see later).
Activation-induced cytidine deaminase (AID; encoded by AICDA) is the master regulator of CSR and somatic hypermutation (SHM) 33 . Deletion of Pten or Foxo1 in B cells impairs immunoglobulin class switching 26, 30, 34, 35 , suggesting that increased PI3K signalling in B cells antagonizes this process. Indeed, addition of a PI3Kδ inhibitor can restore CSR in Pten −/− cells in vitro 35 .
AID is induced by FOXO1, and in vitro-activated Foxo1
−/− B cells (which mimic B cells with GOF PI3Kδ mutations) exhibit impaired CSR, owing partially to the loss of Aicda transcription; however, inefficient CSR was still observed in Pten −/− B cells in the presence of ectopic AID, suggesting that PI3K signalling also regulates CSR by affecting AID function at the post-transcriptional level 26, 34, 35 . During the germinal centre reaction, B cells cycle between the light zone and dark zone. B cells interact with cognate T cells in the light zone and, if they receive the appropriate signals, undergo CSR and then traffic to the dark zone where they proliferate and undergo SHM 36 . When Foxo1 was deleted specifically in germinal centre B cells, CSR was impaired despite normal Aicda transcription and AID protein expression. This suggests that FOXO1 regu lates the targeting of AID to the immunoglobulin gene locus, that FOXO1 targets other genetic loci required for CSR and SHM and/or that Foxo1 deletion in germinal centre B cells affects the expression of other proteins required for CSR 37, 38 . Indeed, Foxo1 ablation or induction of PI3K activity in germinal centre B cells led to the loss of germinal centre dark zones owing to aberrant trafficking of B cells, at least in part as a consequence of lost expression of CXC-chemokine receptor 4 (Cxcr4), which is a target of FOXO1 37, 38 . Hence, failure to expand antigen-specific B cells that have undergone . The BCR co-opts the co-receptor CD19 or the adaptor B cell associated protein (BCAP), both of which have YXXM motifs to which the p85α SH2 domains can bind. IL-4 receptor (IL4-R) co-opts insulin receptor substrate 1 (IRS1), which also has YXXM motifs. The mechanism whereby CXCR5 is coupled to PI3Kδ remains to be defined (indicated by a dotted line). PI3Kδ signalling through phosphatidylinositol lipids and AKT promotes the activation of mechanistic target of rapamycin (mTOR) and suppresses forkhead box O1 (FOXO1) function (via phosphorylation-dependent nuclear export). FOXO1 is a transcription factor that activates the genes encoding recombinase-activating gene (RAG) proteins involved in V(D)J recombination, IKAROS, which is required for early B cell development, CD62L, which is required for homing to lymph nodes and activation-induced cytidine deaminase (AID), which is required for class-switch recombination (CSR) and somatic hypermutation (SHM). The amino acid sensor mTOR contributes to the growth and proliferation of B cells. All proteins coloured in orange have been affected by loss-of-function mutations causing primary immunodeficiency. Of these, only p85α and p110δ have also been affected by gain-of-function mutations causing activated PI3Kδ syndrome (APDS). BLNK, B cell linker protein; DAG, diacylglycerol; mTORC1, mTOR complex 1; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; PLCγ2, phospholipase Cγ2; PKC, protein kinase C; PtdIns(3)P, phosphatidylinositol-3-phosphate; PtdIns(3,4)P 2 , phosphatidylinositol-3,4-bisphosphate; PtdIns(3,4,5)P 3 , phosphatidylinositol-3,4,5-trisphosphate; PtdIns(4,5)P 2 , phosphatidylinositol-4,5-bisphosphate; RHEB, RAS homologue enriched in brain; SHIP, SH2 domain-containing inositol-5-phosphatase; TSC, tuberous sclerosis. selection in the germinal centre light zone is an additional cause of impaired high-affinity class-switched antibody production.
Together, these findings contrast the effects of impaired PI3K signalling versus unrestrained PI3K signalling in B cells: PI3Kδ deficiency in mature B cells impairs TI antibody responses but does not affect CSR or SHM 27 , whereas, hyperactivation of PI3K signalling in mature B cells interferes with CSR and SHM and prevents the expansion of antigen-specific B cell populations in the germinal centre dark zones 26 ,34,35,37,38 (FIG. 1) .
PI3Kδ is required for mouse CD4
+ T cell differenti ation and T reg cell function. If PI3Kδ-deficient B cells can undergo CSR, why then do PI3Kδ-deficient mice fail to respond to T cell-dependent vaccines? The answer relates to the provision of T cell help for B cell development and immunoglobulin class switching. Inducible T cell costimulator (ICOS) is a T cell co-stimulatory receptor and a potent activator of PI3Kδ (FIG. 2) . Mutant mice in which ICOS has been uncoupled from PI3Kδ lack follicular helper T cells (T FH cells) 39 . Similarly, deletion of the p110δ subunit in T cells interferes with the In T cells, the T cell receptor (TCR), inducible T cell costimulator (ICOS) and interleukin-2 receptor (IL-2R) can activate phosphoinositide 3-kinase-δ (PI3Kδ). ICOS contains a YXXM motif in the cytoplasmic domain, which is essential for ICOS-mediated co-stimulation. Precisely how the TCR activates PI3Kδ remains incompletely understood, but TCR ligation is known to induce ζ-chain-associated protein kinase of 70 kDa (ZAP70)-mediated phosphorylation of linker for activation of T cells (LAT). Whether PI3Kδ binds LAT directly or via other adaptor proteins remains to be established. Mechanisms of PI3Kδ activation downstream of IL-2R are even less clear, but a role for Janus kinase 3 (JAK3) has been implicated. PI3Kδ contributes to the downregulation of IL-7Rα and CD62L expression, via the AKT-dependent inactivation and nuclear export of forkhead box O1 (FOXO1), preparing the T cell to exit the lymph nodes and circulate through the vascular systems and organs. PI3Kδ also increases metabolism and contributes to effector T cell-associated phenotypes by promoting activation of mechanistic target of rapamycin (mTOR). DAG, diacylglycerol; GADs, GRB2-related adaptor proteins; IKK, IκB kinase; mTORC1, mTOR complex 1; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-κB; PLCγ2, phospholipase Cγ2; PKC, protein kinase C; PtdIns(3)P, phosphatidylinositol-3-phosphate; PtdIns(3,4)P 2 , phosphatidylinositol-3,4-bisphosphate; PtdIns(3,4,5)P 3 , phosphatidylinositol-3,4,5-trisphosphate; PtdIns(4,5)P 2 , phosphatidylinositol-4,5-bisphosphate; RHEB, RAS homologue enriched in brain; SHIP, SH2 domain-containing inositol-5-phosphatase; TSC, tuberous sclerosis. . These results highlight a dual role for PI3Kδ in antibody production: inactivation of PI3Kδ in B cells, which leads to activation of FOXO transcription factors, is a prerequisite for CSR and SHM 26, 34, 35 , whereas the activation of PI3Kδ in T FH cells is a prerequisite for the provision of help to supports CSR and SHM in B cells 27 . Naive CD4 + T cell differentiation towards the T helper 1 (T H 1), T H 2 and T H 17 cell lineages is delayed or attenuated when PI3Kδ is inhibited [40] [41] [42] . This may reflect a key role for FOXO transcription factors in the suppression of T H cell differentiation, for example by suppressing Ifng (which encodes interferon-γ) 43 , as well as the requirement for mTOR activity to promote T H cell differentiation 44 . A reduction in T H 2 cell responses underpins the resistance of PI3Kδ-deficient mice to experimentally induced asthma, despite elevated IgE levels 25, 45 . In addition, reduced T H 17 cell responses may protect PI3Kδ-deficient mice from experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis 46 . Although PI3Kδ-deficient mice only develop a partial T H 1 cell response to Leishmania major infections, PI3Kδ-deficient mice control L. major infections more effectively than wild-type mice, which is most likely due to defects in a regulatory immune cell population 47 .
PI3Kδ is required for FOXP3
+ regulatory T (T reg ) cell homeostasis and function 48 . PI3Kδ-deficient mice develop colitis because of inappropriate activation of effector T cells by gut microorganisms, and PI3Kδ-deficient T reg cells fail to suppress experimental colitis 22, 48 . Patients taking the PI3Kδ inhibitor idelalisib (Zydelig; Gilead) also develop colitis, probably in part as a result of reduced T reg cell function 49, 50 . However, PI3Kδ-deficent mice, and mice lacking p110δ only in T reg cells mount a more effective immune response against a broad range of tumours than wild-type mice 51 . As with antibody production, these data highlight the dual nature of PI3Kδ, which is required both for optimal cytokine production by effector T cells and for effective T reg cell-mediated tolerance. Whether PI3Kδ inhibition results in impaired or enhanced cell-mediated immune responses is context dependent and therefore difficult to predict (FIG. 3) . Interestingly, inactivation of PI3Kδ results in the hyperresponsiveness of dendritic cells and macrophages to Toll-like receptor ligands, resulting in increased IL-12 production, which may further contribute to increased cell-mediated immune responses upon LOF of PI3Kδ 52 .
PI3Kδ regulates mouse CD8
+ T cell effector functions. PI3Kδ-deficient CD8 + T cells stimulated in vitro are characterized by a reduced abundance of mRNAs encoding proteins associated with inflammation and cytotoxicity, such as IFNγ, granzyme B and perforin 51, 53, 54 . By contrast, the expression of genes regulating the homing of T cells to the lymph nodes, such as Sell (which encodes CD62L), Ccr7 and Klf2 are increased in PI3Kδ-deficient CD8 + T cells stimulated in vitro 55 . Thus, PI3Kδ can regulate the homeostatic trafficking of T cells to the lymph Phosphoinositide 3-kinase-δ (PI3Kδ) activity needs to be dynamically regulated for normal immune cell function, as some cell types and processes require high PI3Kδ activity, whereas others depend on low PI3Kδ activity (for example, if they require forkhead box O1 (FOXO1)-dependent gene transcription). Problems arise if cells cannot increase or suppress PI3Kδ owing to mutations and have chronically low or high PI3Kδ activity. Immunosuppression is associated with loss-of function and gain-of-function mutations affecting PI3Kδ. Illustrated are some key cell types and processes affected by high or low PI3Kδ activity and the consequences of being locked in one state or the other. In the healthy state (top panel), PI3Kδ signalling is low in naive and memory T cells, which are characterized by low mechanistic target of rapamycin (mTOR) and metabolic activity and high expression of FOXO1-dependent lymph node homing receptors. In activated effector T cells, PI3Kδ activity is high as a consequence of T cell receptor (TCR), interleukin-2 receptor (IL-2R) and inducible T cell costimulator (ICOS) signalling. Effector T cells are also characterized by high mTOR and metabolic activity, whereas FOXO1-dependent expression of lymph node homing receptors is reduced. Inhibition of PI3Kδ signalling during thymic development is thought to favour the development of regulatory T (T reg ) cells. However, PI3Kδ activity is required to maintain normal numbers of T reg cells in the peripheral lymphoid tissues and for T reg cells to adopt an effector phenotype and suppress effector T reg cells, especially in peripheral tissues. Maintenance of low-level signalling (also referred to as tonic signalling) via PI3Kδ (and to a lesser extent PI3Kα) maintains survival of naive follicular B cells. Upon activation, PI3Kδ levels are increased and this contributes to B cell proliferation. However, for B cells to undergo class-switch recombination (CSR) in the germinal centre, PI3Kδ signalling needs to be tuned down to allow higher FOXO1 transcription and proper activation-induced cytidine deaminase (AID) targeting. In disease states (bottom panel) caused by gain-of-function or loss-of-function mutations in PIK3CD or PIK3R1 (which encode p110δ and p85α , respectively), the disruption of the proper dynamics of signalling result in cellular defects associated with immunodeficiency. Chronically high PI3Kδ activity leads to abnormalities in T cells -increased senescence, cell death and T reg cell numbers -and in B cells -more transitional B cells and reduced CSR and somatic hypermutation (SHM) -with increased susceptibility to B cell lymphoma, infections and lymphoproliferative disease. Chronically low PI3Kδ activity leads to a different set of abnormalities in T cells (defective T cell responses and reduced T reg cell numbers) and in B cells (low numbers), resulting in prevalent infections and colitis. MZ, marginal zone.
nodes and contributes to the reprogramming of CD8 + T cells to acquire full effector functions and migrate to peripheral tissues.
PI3Kδ is required to reach the optimal magnitude of CD8 + T cell responses in vivo 53, 56 . Nevertheless, PI3Kδ-deficient CD8 + T cells can become fully differentiated cytotoxic T cells that produce IFNγ and granzyme B required for the killing of virus-infected cells or tumours; this suggests that the transcriptional defects described in vitro can, at least in part, be overcome by strong inflammatory stimuli in vivo 51, 53 . Moreover, long-term CD8 + T cell memory responses are intact in PI3Kδ-deficient mice 53 . This is partially because the generation of CD8 + effector T cells is reduced during recall responses, whereas the generation of long-term memory CD8 + T cells in the lymph nodes and bone marrow is preserved 53 . Similarly, the inhibition of the downstream kinase mTOR with low-dose rapamycin during vaccination or infection augments the generation of memory CD8 + T cells at the expense of effector CD8 + T cells 57 . Hence, by promoting mTOR activity, PI3Kδ skews CD8 + T cell differentiation in favour of effector T cells, but antagonizes the generation of memory CD8 + T cells. Thus, strong PI3Kδ activity is associated with effector CD8 + T cell differentiation, whereas the maintenance of CD8 + T cell memory requires the suppression of PI3K signalling (FIG. 3) .
Consequences of hyperactive PI3K signalling in mouse T cells. Similar to B cells, the consequence of PI3Kδ hyperactivation in mouse T cells can be inferred from experiments using PTEN-deficient or FOXO1-deficient T cells. Loss of PTEN expression in early T cell development leads to the development of an immature T cell lymphoma and a hyperactivated T cell phenotype, charac terized by the increased secretion of effector T cell cytokines and autoimmunity 58 . Similar results were observed in mice expressing a mutant p85α protein that lacked inhibitory contacts with the p110 catalytic subunit 59 . Deleting PTEN in mature CD4 + T cells also resulted in enhanced cytokine production and T H cell function, but did not induce T cell transformation or autommunity 60 . Furthermore, loss of Foxo1 leads to a loss of memory CD8 + T cell development after infection 61 . Together, these data indicate a unique sensitivity of thymocytes to PI3Kδ-dependent T cell transformation, and suggest that PI3Kδ signalling also affects central tolerance to self-peptides. Overall, these studies suggest that unrestrained PI3K signalling in T cells lowers their threshold of activation.
Altered PI3Kδ signalling in human PIDs
Both LOF and GOF mutations in PI3K genes that cause PIDs in humans have been described. Our understanding of the underpinning causes of these PIDs has been greatly aided by the use of mouse models (as described in the previous section), but the discovery of these PIDs has also furthered and challenged our understanding of the functions of PI3Kδ (BOX 2 and below).
Loss of function of p85α or p110δ in humans. As with mouse T cells, inhibition of PI3Kδ in human T cells suppresses the expression of effector cytokines such as IFNγ, IL-4 and IL-17 (REF. 41).
A single patient with a homozygous PIK3R1 mutation that generated a premature stop codon (resulting in the loss of p85α and markedly decreased expression of p110δ) presented with recurrent pneumonia associated with agammaglobulin aemia and severe B cell lymphopaenia due to a block in early B cell development 10 . The development of colitis in this patient was attributed to antibody deficiency and the consequent outgrowth of gut pathogens, but it could also be due to T reg cell deficiency 10 . Similarly, one patient lacking p110δ as a result of the inheritance of two different non-functional alleles has been described, and this patient presented with sinopulmonary infections, septic arthritis, inflammatory bowel disease and autoimmune hepatitis, associated with hypogammaglobulinaemia 9 . Loss of p110δ was again associated with severe B cell lymphopaenia and fewer memory T cells 9 . Thus, the two reported patients with a loss of PI3Kδ suffer infections associated with the lack of B cells. Interestingly, in mice, a complete block in B cell development and severe mature B cell lympho paenia are only observed when both the p110α and p110δ are inactivated in the B cell lineage 24 , suggesting a redundancy between these isoforms in mice that is not reflected in humans. The inflammatory and auto immune manifestations in PI3Kδ-deficient humans, possibly associated with
Box 2 | Lessons learnt from APDS
• Although the normal physiological role of phosphoinositide 3-kinase-δ (PI3Kδ) has been extensively studied in mouse models, investigation of patients with activated PI3Kδ syndrome (APDS) has provided important new insights about the biology of this kinase in humans.
• Loss-of-function (LOF) or gain-of-function (GOF) mutations affecting PI3Kδ lead to immunodeficiency. This illustrates how this pathway needs to be dynamically regulated for normal immune cell function.
• The previously reported roles for PI3Kδ in B cell function and humoral immunity did not predict the increase of transitional B cell numbers that have been observed in patients with APDS.
• Defects in class-switch recombination (CSR) that are not attributable to defective AICDA mRNA expression (encoding AID) remain to be fully understood.
• Augmented PI3Kδ results in a loss of naive T cells and an in vivo proliferative burst that causes lymphoproliferative disease and drives T cells towards cellular senescence (a phenotype that is poorly mimicked in mouse models owing to long telomeres).
• Moreover, patient T cells are highly susceptible to T cell receptor (TCR) restimulation-induced cell death, indicating a previously unappreciated role for PI3Kδ in a pro-apoptotic signalling pathway.
• The high proportion of patients with severe respiratory infections and bronchiectasis suggests a role for PI3Kδ in promoting inflammation of the lungs by mechanisms that, although incompletely understood, may indicate a key role for PI3Kδ in airway-associated innate immune responses, in addition to its role in humoral immunity.
• Previously, LOF point mutations in PIK3R1 were shown to cause SHORT (short stature, hyperextensibility of joints, hernia, ocular depression, Rieger anomaly and teething delay) syndrome [88] [89] [90] [91] . It is unclear why the ΔEx11 mutations that cause APDS2 manifest primarily as primary immune deficiency; however, it is of interest to note at least one case where this mutation was suggested to relate to SHORT syndrome 73 . This indicates that PIK3R1 ΔEx11 may have distinct effects on different p110 isoforms in different tissues.
reduced T reg cell function, underscore the importance of PI3Kδ in maintaining self-tolerance. PI3Kδ is also required for the generation of ROS by human neutrophils, and treatment of patients with the PI3Kδ inhibi tor idelalisib can lead to neutropaenia and increased risk of infections 49, 62 . Activating PI3Kδ mutations that underlie human APDS. In 2013, groups in Cambridge (UK) and Bethesda (US) reported whole-exome sequencing studies of patients with uncharacterized PID, which revealed causal heterozygous activating mutations in PIK3CD 1, 2 . The UK patients were identified by screening cohorts of patients with PIDs that had a high frequency of recurrent chest infections and bronchiectasisfeatures suggestive of antibody deficiency -although frequent herpes viral infections and an increased proportion of effector T cells were also noted 1 . The US cohort were identified on the basis of persistent viraemia with herpes family viruses, which are commonly associated with altered T cell or natural killer (NK) cell function, in addition to frequent airway infections 2 . Because both B cells and T cells are affected in these patients, APDS should be characterized as a combined immunodeficiency [1] [2] [3] [4] [5] . This immunodeficiency had previously been noted in a Taiwanese boy by targeted sequencing of the PIK3CD gene in children with B cell immunodeficiency, although the nature of the mutation (GOF or LOF) was not elucidated 63 . Subsequently, a number of additional studies have identified APDS patients with mutations in PIK3CD 5, 7, [64] [65] [66] [67] [68] [69] or PIK3R1 (REFS 6, (70) (71) (72) (73) . Patients with GOF mutations in either of these genes appear to largely phenocopy each other, despite the fact that p85α is ubiqui tously expressed and can pair with p110α and p110β in addition to p110δ. There is some evidence for effects of the PIK3R1 GOF mutations outside the immune system (for example, short stature, see
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. Otherwise, the biochemical and clinical symptoms of patients with APDS1 (PIK3CD mutations) or APDS2 (PIK3R1 mutations) are similar, suggesting that the pathological features of both syndromes are a consequence of aberrant and hyperactive PI3Kδ signalling [1] [2] [3] [4] . Here we use the generic term APDS unless referring specifically to either syndrome. A milder form of APDS-like immunodeficiency has been described in Cowden disease, caused by heterozygous loss of PTEN, although the increases in PtdIns(3,4,5)P 3 and phosphorylated AKT levels in T cells from these patients was less obvious than observed in the T cells from patients with APDS 69, 74, 75 . The most frequent mutation in PIK3CD (c.3061G>A; OMIM 602839) encodes a glutamic acid for lysine substitution at position 1021 (E1021K) of p110δ (TABLE 1) . To date, this mutation has only been found in patients with APDS and their affected family members but not among healthy unrelated subjects 1 . Patients with the E1021K mutation have been found across continents and ethnicities. Genetic analysis showed no founder effect, demonstrating that E1021K is a recurrent mutation that appeared de novo independently in multiple unrelated families 1 . p110δ with the E1021K mutation has increased lipid kinase activity, as shown using recombinant proteins in vitro and by measuring PtdIns(3,4,5)P 3 and AKT phosphorylation levels in patient-derived T cells 1, 2 . The E1021K mutation is located in the carboxy-terminal lobe of the kinase domain of p110δ, similarly to the oncogenic H1047R mutation of p110α, and enhances the membrane association of p110δ in vitro, facilitating more effective phosphorylation of its lipid substrate PtdIns(4,5)P 2 ; this increases the accumulation of PtdIns(3,4,5)P 3 and lowers the activation threshold of PI3Kδ 1, 17 (FIG. 3) . Other missense p110δ mutations -N334K, C416R and E525K -have also been shown to cause APDS, although they are less frequent than E1021K 2 (TABLE 1) . Interestingly, GOF mutations of the homologous amino acid residues of p110α (N345, C420 and E545, respectively) have been identified in tumours (COSMIC) and are thought to interfere with the inhibitory contacts imposed by p85α and hence increase the lipid kinase activity of the p110 subunit 17 ; this implies that a similar mechanism may lead to enhanced PtdIns(3,4,5)P 3 accumulation in cells from patients with APDS with the equivalent mutations and hence the immune modulation seen in APDS (FIG. 4) . APDS is thus distinct from most other PIDs in that it is the hyperactivation of signalling pathways, rather than their inhibition, that leads to immune dysfunction. This distinction offers unique therapeutic opportunities (see below).
A heterozygous splice site mutation before exon 11 of the PIK3R1 gene leads to an in-frame fusion of exon 10 with exon 12, resulting in the deletion of 42 amino acids in p85α (del p.434-475; OMIM 616005), p55α and p50α 3, 4 (FIG. 4) . These amino acids lie in the inter-SH2 domain that regulates the activity of the catalytic p110 subunits 76 . Oncogenic mutations in this region result in mutant proteins that can bind p110 subunits but are less effective at inhibiting their enzymatic activity 76, 77 . Similar to mutations in the p110δ subunit, this is thought to lower the threshold of activation for PI3Kδ. The mutant p85α Δ434-475 (ΔEx11) protein (FIG. 4) was shown to stabilize p110δ, which was expressed at near normal levels in patient cells, but its inhibitory function was impaired, leading to increased PI3Kδ activity 3, 4 . Because the net effect of ΔEx11 is increased PI3Kδ activity, we consider it a GOF mutation, even though it is strictly speaking a mutation resulting in loss of inhibitory function.
Thus, a number of different mutations in PIK3R1 or PIK3CD lead to increased activity of PI3Kδ, either by disrupting inhibitory contacts between p85α and p110δ or by increasing the affinity of p110δ for the plasma membrane, promoting its interaction with the lipid substrate and hence facilitating phosphorylation of PtdIns(4,5)P 2 .
Activating PI3Kδ mutations lead to impaired B cell function and vaccine responses. Immunoglobulin levels in patients with APDS are variable, ranging from isolated specific antibody deficiency or IgG subclass deficiency to severe hypogammaglobulinaemia, often with increased IgM levels. In one cohort, 10% of a heterogeneous PID cohort who suffered recurrent infections were found to . Binding of the p85α SH2 domains to tyrosine-phosphorylated residues on an activated receptor releases the inhibitory contacts between the p85α SH2 domains and the p110δ C2, helical and kinase domains (shown in red in part a). It is possible that the ΔEx11 mutation (red) that truncates the p85α inter-SH2 domain affects p110δ more than it affects p110α, hence the lack of more dramatic pleiotropic effects on growth and metabolism in individuals with this deletion. RAS-GTP further tethers p110δ to the membrane by binding to the RAS-binding domain (RBD) of p110δ. Gain-of-function mutations in PIK3R1 and PIK3CD increase kinase activity by interfering with inhibitory interactions between the p85α regulatory and p110δ catalytic subunit (ΔEx11, N334K, C416R and E525K), or by increasing the affinity of p110δ for the plasma membrane (E1021K). The E1021K mutations may also interfere with inhibitory contacts from the p85α C-SH2 domain 1 (see REF. 17 and references therein for further details of the structures and mechanisms of regulation of PI3Kδ). BH, breakpoint-cluster region homology domain; C, carboxy-terminal; i, inter; N, amino-terminal; P, proline-rich region; PtdIns(3,4,5)P 3 , phosphatidylinositol-3,4,5-trisphosphate; PtdIns(4,5)P 2 , phosphatidylinositol-4,5-bisphosphate; SH, SRC-homology domain. 1, 3 . In vitro, B cells from patients with APDS showed impaired CSR (consistent with the observed tendency for these patients to have reduced IgG and increased IgM levels) but, in contrast to the findings in mouse cells, this was not associated with reduced AICDA mRNA levels 2 . As noted above, it is possible that PI3K regulates AID function by post-transcriptional mechanisms as well as by regulation of mRNA expression 35 . Alternatively, the defective CSR in APDS patients could be due to defects in germinal centre T FH cells 78 , aberrant B cell maturation and/or defective migration of B cells during the germinal centre reaction in the spleen, as shown for FOXO1-deficient B cells in mice 37, 38 . The basis for the increased percentage of circulating transitional B cells in patients with APDS remains incompletely understood but is likely to be a consequence of impaired B cell maturation and/or an increased propensity for mature B cells to undergo apoptosis 1 . These findings are in marked contrast to the dramatic loss of B cells and agamma globulin aemia seen in the rare patients with LOF mutations in PIK3R1 or PIK3CD 9, 10 . Encapsulated bacteria (such as Haemophilus influenzae and Streptococcus pneumoniae) are the most frequent respiratory isolates from patients with APDS
, which is consistent with a substantial defect in antibody-mediated immunity. However, the severity of respiratory infections and resulting structural damage in the lungs do not correlate well with the reduction in B cell numbers or the extent of immunoglobulin deficiency 6, 7 , and immunoglobulin replacement therapy alone does not seem to limit the progress of lung damage in patients with APDS 6, 7 . One explanation for this apparent discrepancy is that PI3Kδ hyperactivation causes additional defects (such as altered T cell functions or innate immune cell dysfunction) that also contribute to an increased susceptibility to respiratory bacterial infections. As mentioned above, PI3Kδ has been shown to promote ROS production by human neutro phils, which could cause collateral damage if excessively produced during infections 62 . However, analysis of APDS patient neutrophils did not reveal an obvious increase in ROS production, or indeed in PtdIns(3,4,5)P 3 production, in response to stimulation with microbial peptides 1 . Nonetheless, the increased susceptibility of patients with APDS to staphylo coccal skin infections and abscess formation 1, 65 , as well as defective killing of myco bacteria by macrophages from a patient with APDS 64 , suggest that abnormalities may indeed exist in the innate immune system which remain to be more completely investigated. Increased PI3K activity has been shown to compromise the migratory accuracy of neutrophils, and hence prolong their tissuetransit time, leading to increased opportunities for bystander tissue injury mediated by surface-associated neutrophil proteases 79 . Hence a wide range of impaired immune cell functions, affecting both innate and adaptive immune responses, may contribute to recurrent infection and bronchiectasis in patients with APDS.
Activating PI3Kδ mutations cause T cell senescence.
Peripheral blood analysis revealed an increase in effectortype T cells with a severe reduction in naive T cell numbers [1] [2] [3] [4] . Freshly isolated peripheral blood cells from patients with APDS demonstrated reduced secretion of cytokines and increased apoptosis upon TCR restimulation [1] [2] [3] . Unexpectedly, acute PI3Kδ inhibition in T cells from APDS patients reduced TCR-triggered apoptosis, suggesting a previously unappreciated role for PI3Kδ signalling in pro-apoptotic pathways 1, 3 . However, T cell blasts that had escaped apoptosis and expanded after activation in vitro showed increased production of IFNγ, tumour necrosis factor and granzyme B 2 . Thus, chronic hyperactivation of PI3Kδ signalling promotes T cell differentiation into terminal effector cells with increased sensitivity to TCR-induced cell death and dysregulation of cytokine secretion.
Notably, the expression of CD57, which is a marker of senescence on CD8 + T cells 80 + T cell senescence in APDS is likely to be distinct from T cell exhaustion driven by chronic viral infections. T cell senescence due to telomere shortening results in cell cycle arrest while maintaining most other responses to antigen 81 , whereas T cell exhaustion from chronic antigen stimulation results in the upregulation of co-inhibitory receptors that broadly dampen TCR signalling and antigen responsiveness 82 . These findings point to in vivo hyperproliferation (which is consistent with enlarged spleen and lymph nodes) as the underlying cause of the T cell senescence and short telomeres in patients with APDS and support the connection between cell division and effector T cell differentiation.
T cells from patients with APDS exhibit increased activity of mTOR 2 , a key mediator of the switch from a catabolic naive state to an anabolic effector state during a T cell response 83 . Increased glucose uptake is also observed in T cells from APDS patients compared with healthy subjects 2, 4 . These findings indicate that changes in T cell metabolism induced by hyperactive PI3Kδ signalling may underlie the hyperproliferation associated with T cell senescence in patients with APDS. Further studies will be needed to determine whether elevated mTOR activity is a direct consequence of increased PI3Kδ activity or whether it also reflects the skewed effector phenotype of T cells in patients with APDS. PI3Kδ inhibition reduced, but did not ablate, phosphorylation of S6K (a component of the mTOR signalling pathway) in APDS T cells, confirming that PI3Kδ contributes to mTOR activity in these cells 4 . Therefore, unrestrained and prolonged PI3Kδ and mTOR activity may drive APDS T cells towards senescence rather than allowing T cells to revert to a metabolically quiescent phenotype after antigen exposure (FIG. 3) .
The main clinical manifestation of abnormal T cell function in APDS is herpes viral infection. All of the patients with PIK3CD mutations that were described by Lucas et al. 3 experienced chronic Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV) viraemia; in other studies the occurrence of CMV and/or EBV was lower 1, [4] [5] [6] [7] , although herpes simplex virus and varicella zoster virus infections were also noted. These inter-study differences may reflect the case-finding strategies, immune profiles and/or pathogen exposure of the patients. Surprisingly, given the abnormal T cell profiles, few other opportunistic infections have been reported. Some cases of problematic viral warts and molluscum contagiosum have been identified 7 , perhaps suggesting impaired NK cell function, but this has yet to be confirmed experimentally.
Treatment options for patients with APDS
As patients with APDS often present with reduced IgG levels or respond poorly to vaccines, many are treated with immunoglobulin replacement therapy that is often supplemented with prophylactic antibiotics. Although this may have been effective in some patients, it has not prevented the acquisition or progression of bronchiectasis in others, even when the treatment was initiated in childhood 6, 7 . Haematopoietic stem cell transplantation (HSCT) is a treatment option, particularly for younger patients. HSCT could also help prevent or treat malignant B cell transformation, which occurs in 10-15% of patients. Several patients have undergone HSCT and, although significant improvements have been noted 6, 7 , the follow up of these patients is too short to make a definitive conclusion.
Rapamycin. Lucas and colleagues reported use of the mTOR inhibitor rapamycin in one patient, who showed a dramatic reduction in lymphadenopathy and hepatosplenomegaly and improvement in T cell subset defects 2 . Similar improvements have been noted in a recent case report of a four year old boy also treated with rapamycin 68 . However, the effect of rapamycin on B cell homeostasis and humoral immune responses in APDS patients remains to be determined. It is important to keep in mind that PI3Kδ regulates other pathways in addition to mTOR and, conversely, that mTOR is also regulated by PI3K-independent pathways 8 . Moreover, mTOR regu lates the expression of PTEN such that treatment of T cells with rapamycin can actually increase PI3K signalling in T cells 84 , potentially exacerbating aspects of hyperactive PI3Kδ signalling in APDS.
PI3Kδ inhibitors. The PI3Kδ inhibitor idelalisib is licenced for use in chronic lymphocytic leukaemia and non-Hodgkin lymphoma 85, 86 . However, idelalisib has a considerable side-effect profile, including pneumonitis, pneumonia, transaminitis and colitis 49 . Histologically, the colitis in these patients is reminiscent of that seen in mice lacking functional PI3Kδ, suggesting it is an ontarget effect rather than a compound-specific effect 49 . It is possible that APDS patients will benefit from lower doses of PI3Kδ inhibitors than those required for the treatment of B cell lymphomas and hence may be spared some of the more severe side effects. Another possibility is that topical administration of the PI3Kδ inhibitor may avoid some of the adverse effects.
Two clinical trials of PI3Kδ inhibitors in patients with APDS have recently been announced: NCT02435173 sponsored by Novartis for an oral PI3Kδ inhibitor and NCT02593539 sponsored by GlaxoSmithKline for an inhaled PI3Kδ inhibitor. To correct systemic immune defects, including lymphoproliferation and lymphoma, an oral inhibitor is more likely to be effective; however, an inhaled inhibitor is expected to have a better safety profile and may be appropriate for patients who are primarily affected by airway infections and potentially may limit progression of bronchiectasis.
Conclusions GOF mutations in PI3Kδ cause a range of B cell and T cell developmental and functional defects that compromise host defence, leading to recurrent bacterial and viral infections
. This distinguishes APDS patients from patients with LOF of PI3Kδ who present with much more severe B cell lymphopaenia and agammaglobulinaemia, but not T cell senescence. In general, GOF mutations are unusual causes of immunodeficiency 87 . The therapeutic options for LOF of PI3Kδ may be limited to immunoglobulin replacement therapy, bone marrow transplants and perhaps gene therapy. Although these are also options for APDS, existing (mTOR inhibitors) and emerging (PI3Kδ inhibitors) therapeutics offer the additional possibility of correcting the biochemical defects that arise from APDS-associated mutations, and the impact of these agents is currently being explored.
The fact that both LOF and GOF PI3Kδ mutations lead to immunodeficiencies highlights the concept that this pathway must be precisely and dynamically modulated for optimal immune cell function: too much, too little or the inability to turn the pathway on or off as needed, has detrimental consequences 8 (FIG. 3) . These considerations raise the possibility that aberrant PI3K signalling in immune cells may also occur in nongenetic diseases or conditions that lead to increased susceptibility to infections.
Many fundamental questions remain to be answered. How common is APDS among patients with PID? What are some of the genetic or environmental influences that lead to the clinical heterogeneity of patients with APDS? Are there mutations in other genes that lead to hyperactivation of PI3Kδ and APDS-like syndromes? Why do APDS T cells undergo apoptosis when stimulated? Why does recurrent airway infection lead to bronchiectasis more frequently in patients with APDS than in those with other PIDs? Can PI3Kδ inhibitors restore normal immune function in APDS? The answers to these and further questions will require more detailed analysis of APDS cohorts, genetic screening of larger PID cohorts, and establishment of mouse models that mimic this intriguing new disease and help evaluate different therapeutic strategies.
